QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.004622v1 33/10/1477    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimizu, M. Articles by Sugiyama, Y. Search for Related Content PubMed PubMed Citation Articles by Shimizu, M. Articles by Sugiyama, Y.

CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS

Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan (M.S., K.F., K.O., R.N.); and Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (K.M., H.K., Y.S.)

Fexofenadine hydrochloride (FEX), a second generation H₁-receptor antagonist, is mainly eliminated from the liver into bile in unchanged form. Recent studies have shown that FEX can be accepted by human MDR1 (P-glycoprotein), OATP1A2 [organic anion-transporting polypeptide (OATP)-A, and OATP2B1 (OATP-B)] expression systems. However, other transporters responsible for the hepatic uptake of FEX have not yet been identified. In the present study, we evaluated the contribution of OATP family transporters, namely OATP1B1 (OATP2/OATP-C), OATP1B3 (OATP8), and OATP2B1 (OATP-B), to FEX uptake using transporter-expressing HEK293 (human embryonic kidney) cells. The uptake of FEX in OATP1B3-expressing cells was significantly greater than that in vector-transfected cells. On the other hand, OATP1B1- or OATP2B1-mediated uptake of FEX was not statistically significant. OATP1B3-mediated transport could be explained by a one-saturable component with a Michaelis constant (K_m) of 108 ± 11 µM. The inhibitory effect of FEX on the uptake of estrone-3-sulfate (E₁S), cholecystokinin octapeptide (CCK-8), and 17ß-estradiol-17ß-D-glucuronide (E₂17ßG) was also examined. Both OATP1B1- and OATP1B3-mediated E₂17ßG uptake was inhibited by FEX. The K_i values were 148 ± 61 and 205 ± 72 µM for OATP1B1 and OATP1B3, respectively. FEX also inhibited OATP1B3-mediated CCK-8 uptake and OATP1B1-mediated E₁S uptake with a K_i value of 83.3 ± 15.3 and 257 ± 84 µM, respectively, suggesting that FEX could not be used as a specific inhibitor for OATP1B1 and OATP1B3, although FEX was preferentially accepted by OATP1B3. In conclusion, this is, to our knowledge, the first demonstration that OATP1B3 is thought to be a major transporter involved in hepatic uptake of FEX in humans.

This article has been cited by other articles:

				E. Garver, E. D. Hugger, S. P. Shearn, A. Rao, P. A. Dawson, C. B. Davis, and C. Han Involvement of Intestinal Uptake Transporters in the Absorption of Azithromycin and Clarithromycin in the Rat Drug Metab. Dispos., December 1, 2008; 36(12): 2492 - 2498. [Abstract] [Full Text] [PDF]

				H. Zaher, H. E. M. zu Schwabedissen, R. G. Tirona, M. L. Cox, L. A. Obert, N. Agrawal, J. Palandra, J. L. Stock, R. B. Kim, and J. A. Ware Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin Mol. Pharmacol., August 1, 2008; 74(2): 320 - 329. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF]

				N. Ishiguro, K. Maeda, A. Saito, W. Kishimoto, S. Matsushima, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide Drug Metab. Dispos., April 1, 2008; 36(4): 796 - 805. [Abstract] [Full Text] [PDF]

				A. Yamada, K. Maeda, E. Kamiyama, D. Sugiyama, T. Kondo, Y. Shiroyanagi, H. Nakazawa, T. Okano, M. Adachi, J. D. Schuetz, et al. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor Drug Metab. Dispos., December 1, 2007; 35(12): 2166 - 2176. [Abstract] [Full Text] [PDF]

				A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]

				J. Noe, R. Portmann, M.-E. Brun, and C. Funk Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos., August 1, 2007; 35(8): 1308 - 1314. [Abstract] [Full Text] [PDF]

				T. Uno, M. Shimizu, K. Sugawara, and T. Tateishi Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine Drug Metab. Dispos., November 1, 2006; 34(11): 1875 - 1879. [Abstract] [Full Text] [PDF]

				B. Kirby, E. D. Kharasch, K. T. Thummel, V. S. Narang, C. J. Hoffer, and J. D. Unadkat Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities. J. Clin. Pharmacol., November 1, 2006; 46(11): 1313 - 1319. [Abstract] [Full Text] [PDF]

				M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 Drug Metab. Dispos., July 1, 2006; 34(7): 1229 - 1236. [Abstract] [Full Text] [PDF]

				N. Ishiguro, K. Maeda, W. Kishimoto, A. Saito, A. Harada, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS Drug Metab. Dispos., July 1, 2006; 34(7): 1109 - 1115. [Abstract] [Full Text] [PDF]

				N. Petri, E. Bergman, P. Forsell, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL Drug Metab. Dispos., July 1, 2006; 34(7): 1182 - 1189. [Abstract] [Full Text] [PDF]

				W. Yamashiro, K. Maeda, M. Hirouchi, Y. Adachi, Z. Hu, and Y. Sugiyama INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS Drug Metab. Dispos., July 1, 2006; 34(7): 1247 - 1254. [Abstract] [Full Text] [PDF]

				H. Tahara, H. Kusuhara, K. Maeda, H. Koepsell, E. Fuse, and Y. Sugiyama INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID Drug Metab. Dispos., May 1, 2006; 34(5): 743 - 747. [Abstract] [Full Text] [PDF]

				K. Letschert, H. Faulstich, D. Keller, and D. Keppler Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes Toxicol. Sci., May 1, 2006; 91(1): 140 - 149. [Abstract] [Full Text] [PDF]